A comparison of bladder volumes based on treatment planning CT and BladderScan® BVI 6100 ultrasound device in a prostate radiation therapy population

• Published in: British journal of radiology Vol. 91; no. 1091; p. 20180160
• Main Authors: Mullaney, Laura, O'Shea, Evelyn, Dunne, Mary T, Thirion, Pierre G, Armstrong, John G
• Format: Journal Article
• Language: English
• Published: England The British Institute of Radiology 01.11.2018
• Subjects: Equipment Design; Humans; Male; Organ Size; Patient Care Planning; Prostatic Neoplasms - radiotherapy; Short Communication; Ultrasonography - instrumentation; Urinary Bladder - anatomy & histology; Urinary Bladder - diagnostic imaging
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr.20180160

The aim of this study is to investigate if a handheld ultrasound device (BladderScan® BVI 6100) can accurately measure bladder volumes in prostate radiotherapy (RT) patients. A comparison was made of contoured bladder volumes based on treatment planning CT (TPCT) and BladderScan® BVI 6100 ultrasound device in a large prostate RT population. Three bladder volume (BV) measurements were taken using the bladder volume instrument (BVI) device on prostate RT patients immediately prior to TPCT (n = 190). The CT delineation bladder volumes were also recorded. The mean of the three BVI readings (BVI ) and the maximum (BVI ) of the readings were considered for a comparative analysis. There was a strong positive correlation between the BVI and CT delineated bladder volumes (BVI r = 0.825; BVI r = 0.830). The mean difference [± standard deviation (SD)] was an underestimation of BV for both BVI and BVI (44.8 ± 88.2 ml and 32.9 ± 87.5 ml, respectively). This is the largest study to date (n = 190), assessing the accuracy of the BladderScan® BVI 6100 in the prostate RT population. The BVI 6100 provides an acceptable indication of BV for use in prostate RT patients for the purposes of monitoring BV. The BladderScan® BVI 6100 provides a convenient and non-irradiating method of indicating BV for use in prostate RT patients.